Strs Ohio Acquires 40,900 Shares of Dynavax Technologies Corporation $DVAX

Strs Ohio raised its stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 196.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,700 shares of the biopharmaceutical company’s stock after acquiring an additional 40,900 shares during the quarter. Strs Ohio owned approximately 0.05% of Dynavax Technologies worth $613,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in DVAX. Osaic Holdings Inc. increased its position in Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,226 shares in the last quarter. Callan Family Office LLC bought a new stake in shares of Dynavax Technologies during the second quarter worth $107,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Dynavax Technologies during the second quarter worth $121,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Dynavax Technologies during the third quarter worth $122,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in shares of Dynavax Technologies in the 2nd quarter valued at $127,000. 96.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, January 21st. William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Finally, Wall Street Zen raised Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Dynavax Technologies currently has an average rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $15.48 on Friday. The business’s 50-day moving average price is $13.44 and its two-hundred day moving average price is $11.46. Dynavax Technologies Corporation has a 12 month low of $9.20 and a 12 month high of $15.73. The firm has a market capitalization of $1.82 billion, a PE ratio of -41.84 and a beta of 0.89. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The company had revenue of $94.88 million during the quarter, compared to the consensus estimate of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. On average, analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Insider Transactions at Dynavax Technologies

In other news, COO David F. Novack sold 114,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the transaction, the chief operating officer owned 63,344 shares in the company, valued at approximately $990,700.16. The trade was a 64.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.98% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.